mRNA/Gene Therapy Technology: Futile, Deadly, but Hugely Profitable - Part 2

Senior officials at the FDA work to grow the market of severely ill and dying children.

Continued from Part 1. Futile but hugely profitable is the nature of the scam with “orphan drugs” for “rare genetic conditions”. There is great interest in it from the highest ranks at the FDA.

Peter Marks, Director of CBER FDA, recently overrode reviewers’ call to reject Sarepta’s new Duchenne gene therapy.